Mechanistic Pharmacokinetics and Pharmacodynamics

摘要 该计划首先寻求增加对药代动力学(PK)和机制的了解。 皮质类固醇(CS)对与内分泌相关的基因组、蛋白质组和生理过程的影响 CS从局部到系统水平的代谢和药理反应急性和慢性给药。 第二，提供潜在联合治疗的多种药物的作用机制和相互作用 将对胰腺癌进行检查。第三，这些具体的研究成果将与相关的 来自文献的信息，以开发改进的基于机制的PK和药效学(PK/PD) 模型和方法跨越并提供基本的、复杂的和系统的药理学层面的见解。 总体而言，我们的目标是开发揭示和相互关联的机械性药理学和疾病模型 《生物学和药理学规则》在生物组织的不同层面上，并允许改进 体内激素和药物效应的定量和预测。抗癌药物研究利用细胞培养， 蛋白质组学和网络分析，重点是寻求多种因素和进化的自然协同作用 量化药物相互作用的新方法。我们的CS研究的实验范例很大 在接受特定条件或药物治疗的动物群体中进行的仔细对照研究(“巨鼠” 研究)。血液和主要器官将在一段时间内从雄性和雌性大鼠身上采集，反映出 内源性生物节律或由单一药物剂量或延长所产生的变化的开始和恢复 疾病和慢性药物暴露造成的动态平衡紊乱。我们调查了参与 短节律(昼夜节律)在较长的生物节律(发情周期、季节)中，评估疾病中的性别差异 过程和类固醇的作用，特别是在类风湿性关节炎中，并进化和应用生理学相关 从基本的PK/PD到广泛的系统药理学方法。我们的方法和跨学科合作 包括广泛基于实验室的实验、最先进的生物分析方法、生成“大数据” 一组组学反应数据、各种计算平台、关于不同生物学的专家知识 过程，并提供想象力和洞察力，以认识到出现的新原则并作为 药物、激素和天然化合物如何在体内起作用和相互作用的复杂性。这些努力 涵盖并丰富了基本的PK/PD和系统建模，但重点是增强的生理学 参与复杂的药物作用机制的模型。这些整体研究和数学建模 创新将改善对关键生物学、激素和药理学的多尺度理解 功能，并将继续在定量药理学中提供广泛的应用。

Abstract This program seeks firstly to provide increased understanding of pharmacokinetics (PK) and mechanisms of corticosteroid (CS) effects on genomic, proteomic, and physiologic processes associated with endocrine, metabolic, and pharmacologic responses from local to systems levels for CS dosed acutely and chronically. Secondly, the mechanisms of action and interaction of multiple agents offering potential joint therapy of pancreatic cancer will be examined. Thirdly, these specific study results will be integrated with relevant information from the literature to develop improved mechanism-based PK and pharmacodynamic (PK/PD) models and methods spanning and offering insights at basic, complex, and systems pharmacologic levels. Overall, our goals are development of mechanistic pharmacologic and disease models that reveal and interrelate the `rules of biology and pharmacology' at various levels of biological organization and allow improved quantitation and prediction of in vivo hormone and drug effects. The cancer drug studies utilize cell cultures, proteomics, and network analyses with an emphasis on seeking natural synergy of multiple agents and evolving new methods for quantitating drug interactions. Our experimental paradigm for CS studies has been large carefully controlled studies in groups of animals subjected to defined conditions or drug treatments (“giant rat” studies). Blood and major organs will be harvested from male and female rats over timeframes reflecting either endogenous biorhythms or the onset and recovery of changes produced by single drug doses or prolonged disturbances of homeostasis produced by disease and chronic drug exposures. We examine involvement of short rhythms (circadian) within longer biorhythms (estrous cycle, seasons), assess sex differences in disease processes and steroid actions particularly in rheumatoid arthritis, and evolve and apply physiologically relevant basic PK/PD to extensive systems pharmacologic approaches. Our methods and interdisciplinary collaborations include extensive laboratory-based experiments, state-of-the-art bioanalysis methods, generation of “big data” sets of –omics response data, various computational platforms, expert knowledge about diverse biological processes, and offer the imagination and insights to recognize new principles that emerge and underlie the complexities of how drugs, hormones, and natural compounds work and interact in the body. These efforts encompass and enrich both basic PK/PD and systems modeling, but with emphasis on enhanced physiological models that attend complex mechanisms of drug action. These holistic studies and mathematical modeling innovations will provide improved multi-scale understanding of critical biological, hormone, and pharmacologic functions and will continue to offer wide applications in quantitative pharmacology.